Effects of divalent cations, trypsin, and phospholipases on the passive permeability to sodium of inside-out vesicles from human red cells.
Inside-out vesicles (IOV) were prepared from human red blood cells. Steady-state uptake of 23Na was observed to generally follow an exponential time course with a rate constant of 1.57 +/- 0.09 h-1 (SE). One week of cold storage (0-4 degrees C) increased the rate constant to 2.50 +/- 0.12 h-1 (SE). Mg2+, Ca2+, or Sr2+ decreased the rate of 22Na uptake with no observable differences between the three divalent cations when tested at concentrations of 50 microM. Mg2+ was shown to decrease the rate of 22Na uptake at concentrations as low as 5 microM with maximal effect at 50 to 100 microM. The decrease in rate of 22Na uptake induced by Mg2+ could be enhanced by exposure of IOV to Mg2+ for longer periods of time. Trypsin treatment of OIV increased the rate of uptake of 22Na and was dependent on the concentration of trypsin added between 5 to 25 micrograms/ml (treated for 5 min at 25 degrees C). The ability of Mg2+ (50 microM) to decrease the rate of 22Na uptake was still observed after maximal trypsin treatment. Phospholipase A2 or phospholipase C treatment of IOV increased the rate of 22Na uptake and was dependent on the amount of phospholipase A2 (0.1 to 1.0 units/ml) or phospholipase C (0.25 to 2.5 units/ml) added (treated for 5 min at 25 degrees C). After phospholipase A2 treatment, the observed decrease in the rate of 22Na uptake induced by Mg2+ (50 microM) was generally greater than controls. After phospholipase C treatment, the observed decrease in rate of 22Na uptake induced by Mg2+ (50 microM) was less or absent when compared with controls. Phospholipase C treatment was less effective in preventing the Mg2+ effect the longer IOV were exposed to Mg2+. The results suggest that Mg2+ binds to phospholipid headgroups to reduce Na permeability perhaps by inducing a change in bilayer structure or phospholipid association.
D002413:Cations, Divalent; D002463:Cell Membrane Permeability / Q000187:drug effects*; D004910:Erythrocyte Membrane / Q000378:metabolism*; D004912:Erythrocytes / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D010740:Phospholipases / Q000494:pharmacology*; D010741:Phospholipases A / Q000494:pharmacology; D054467:Phospholipases A2; D012964:Sodium / Q000378:metabolism*; D014357:Trypsin / Q000494:pharmacology*; D010738:Type C Phospholipases / Q000494:pharmacology
D002413:Cations, Divalent; D012964:Sodium; D010740:Phospholipases; D010741:Phospholipases A; D054467:Phospholipases A2; D010738:Type C Phospholipases; D014357:Trypsin